| 207 | 2 | 26 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨1例子宫内膜癌患者化疗后引起迟发性腹泻的原因及药学监护。方法分析导致患者发生迟发性腹泻的原因、机制、遗传因素和治疗过程。结果该患者腹泻主要与曾接受过多次放化疗史及基因多态性相关。该患者腹泻的治疗方案安全有效,临床药师在治疗过程中发挥了重要作用。结论加强高风险腹泻化疗患者的药学监护十分重要。
Abstract：[1] RICHARDSON G,DOBISH R. Chemotherapy induced diarrhea[J]. J Oncol Pharm Practice,2007,13(4):181.
[2]ANDREYEV J,ROSS P,DONNELLAN C,et al. Guidance on the management of diarrhea during cancer chemotherapy[J]. Lancet Oncol,2014,15(10):447.
[3]FUCCIO L,GUIDO A,ANDREYEV HJN. Management of intestinal complications in patients with pelvic radiation disease[J]. Clin Gastroenterol Hepatol,2012,10:1326.
[4]李鹏,石萍,王真,等.我院伊立替康用于晚期恶性肿瘤致不良反应56例分析[J].中国药房,2016,27(5):635.
[5]HICKS L D,HYATT J L,STODDARD S,et al. Improved,selective,human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin(Irinotecan; CPT-11)toxicity[J]. J Med Chem,2009,52(12):3742.
[6]赵霞,李妍,徐巍,等.伊立替康致重度迟发性腹泻及骨髓抑制[J].药物不良反应杂志,2014,16(3):183.
[7]XU J M,WANG Y,GE F J,et al. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms[J].World J Gastroenterol,2013,19(24):3899.
[8]CHEN S,YUEH M F,BIGO C,et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan(CPT-11)[J]. Proc Natl Acad Sci USA,2013,110(47):19143.
[9]GAO J,ZHOU J,LI Y,et al. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients[J]. Med Oncol,2013,30(3):1.
[10]LU Y Y,HUANG X E,WU X Y,et al. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan[J]. Asian Pac J Cancer Prev,2014,(7):3335.
[11]IYER L,DAS S,JANISCH L,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity[J]. Pharmacogenomics J,2002,2(1):43.
[12]郭永忠.奥曲肽不同给药方法治疗术后早期炎性肠梗阻的效果对比[J].海峡药学,2012,24(3):202.
[13]陈春华,邱立华.消化道肿瘤化疗相关性腹泻的菌群分布及治疗研究[J].临床消化病杂志,2006,18(2):89.
[14] RICHARDSON G,DOBISH R,PHARM B. Chemotherapy induced diarrhea[J]. J Oncol Pharm Practice,2007,13(4):181.
[15]LIN X B,DIELEMAN L A,KETABI A,et al. Irinotecan(CPT-11)chemotherapy alters intestinal microbiota in tumour bearing rats[J]. PLo S One,2012,7(7):e39764.
[16]许春进,韩敏,徐峰,等.化疗药物对胃癌患者肠道菌群谱的影响及益生菌干预作用的临床研究[J].中华消化病与影像杂志,2016,6(4):154.
[17] HEMARAJATA P,VERSALOVIC J. Effects of probiotics on gut microbiota:mechanisms of intestinal immunomodulation and neuromodulation[J]. Therap Adv Gastroenterol,2013,6(1):39.
[18]张敬,史晓宇,孟玮,等.伊立替康联合奈达铂二线治疗小细胞肺癌临床疗效观察[J].河北北方学院学报,2016,32(2):23.
[19]中国医师协会肿瘤医师分会、中国抗癌协会肿瘤临床化疗专业委员会.中国重组人粒细胞集落刺激因子在肿瘤化疗中的临床应用专家共识[J].中华医学杂志,2015,95(37):3001.
[20] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:myeloid growth factors(version1)[EB/OL].[2016-11-05]. https://www. nccn. org/professionals/physician_gls/default. aspx.
基本信息:
DOI：10.19577/j.1007-4406.2018.03.014
中图分类号:R737.33;R969
引用信息:
[1]宋秋艳,张程亮.对1例子宫内膜癌患者化疗后引起迟发性腹泻的药学监护[J].中国临床药学杂志,2018,27(03):205-208.DOI:10.19577/j.1007-4406.2018.03.014.
2018-05-25
2018-05-25